• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CRISPR Therapeutics (CRSP) Is Down 10.4% After EPS, Revenue Expectations Diverge From Valuation Concerns

    Simply Wall St·07/17/2026 22:34:19
    Listen to the news
    • In recent sessions, CRISPR Therapeutics AG has come under pressure as investors weigh its pending earnings report, expected to show an earnings per share improvement and very large year-over-year revenue growth compared with the prior-year quarter.
    • This tension between anticipated stronger revenue trends and persistent worries about operating performance, financial health, and a very high valuation is shaping how investors reassess the company’s position today.
    • With recent returns under pressure, we’ll explore how expectations for improved earnings per share are influencing CRISPR Therapeutics’ broader investment narrative.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    What Is CRISPR Therapeutics' Investment Narrative?

    To own CRISPR Therapeutics today, you really have to believe in the long-term potential of gene-editing and the company’s ability to convert its CASGEVY partnership and broader pipeline into meaningful, recurring revenue, despite years of small sales and large losses. The recent six-day slide and fresh worries about valuation and financial health come just as the market is bracing for an earnings report expected to show better EPS and very large year-over-year revenue growth. That combination keeps near-term catalysts focused squarely on evidence of commercial traction and cash burn discipline, rather than index additions or past approvals. If the upcoming results confirm only modest operational progress relative to expectations, the latest share-price weakness suggests the news may already be partly reflected, but it also raises the bar for future data and partnership updates.

    Despite retreating, CRISPR Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much.

    Exploring Other Perspectives

    CRSP 1-Year Stock Price Chart
    CRSP 1-Year Stock Price Chart

    Four fair value estimates from the Simply Wall St Community range from about US$86 to over US$220, underscoring how far apart individual views can be on CRISPR Therapeutics. Set those against the recent share-price slide and persistent concerns about high valuation and deep losses, and you can see why the next few earnings reports and any updates on commercial uptake may significantly influence how investors reassess the company’s progress. If you are weighing these varied opinions, it is worth comparing them with your own expectations for cash burn, revenue visibility and risk tolerance over the coming years.

    Explore 4 other fair value estimates on CRISPR Therapeutics - why the stock might be worth just $86.21!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready For A Different Approach?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.